Researchers from Central Drug Research Institute (CDRI) and Academy of Scientific & Innovative Research (AcSIR) have discovered novel antiplasmodial agents.
Aegis Life Inc. and its parent company Entos Pharmaceuticals Inc. (Entos) have entered into a grant agreement with the Bill & Melinda Gates Foundation in the area of infectious disease.
Researchers from Fundacio Privada Instituto de Salud Global Barcelona (ISGLOBAL), Institut de Bioenginyeria de Catalunya (IBEC) and Universitat de Barcelona have described compounds reported to be useful for the treatment of malaria.
Glaxosmithkline Intellectual Property Ltd. has synthesized cytochrome bc1 complex (complex III) (Plasmodium falciparum) inhibitors reported to be useful for the treatment of malaria.
A new acute coronary syndrome detection system developed by Neuome Peptides Pte. Ltd.’s aims to make tests for the frequently lethal condition faster, more precise and less invasive. Neuome’s Truheart is a point-of-care assay for cardiovascular disease that is used in the company’s established Instadetect assay development platform. The assay measures the biomarkers troponins I and T and myoglobin.
Scientists from the University of Delhi and affiliated organizations have reported the discovery and preclinical characterization of novel compounds with antiplasmodial activity.
